Regulus Therapeutics

Regulus Therapeutics

Employees:
80
Market Cap:
$110.85 million
Revenue:
$1.1 million
5 Year Trend:
38.7%
Net Income:
$-81.62 million
NASDAQ:
RGLS

Regulus Therapeutics Inc. or Regulus (NASDAQ: RGLS) is a biopharmaceutical company focused on the development of microRNA-based drugs targeting fibrosis, metabolism and cardiovascular diseases, cancer, HCV and immune-related diseases. Regulus was established in September 2007 by Alnylam Pharmaceuticals and Isis Pharmaceuticals. Wikipedia

Regulus Therapeutics

Employees:
80
Market Cap:
$110.85 million
Revenue:
$1.1 million
5 Year Trend:
38.7%
Net Income:
$-81.62 million
NASDAQ:
RGLS

Regulus Therapeutics Inc. or Regulus (NASDAQ: RGLS) is a biopharmaceutical company focused on the development of microRNA-based drugs targeting fibrosis, metabolism and cardiovascular diseases, cancer, HCV and immune-related diseases. Regulus was established in September 2007 by Alnylam Pharmaceuticals and Isis Pharmaceuticals. Wikipedia